白三烯受体拮抗剂治疗PIF-COPD的临床效果
|
摘要
目的评价白三烯受体拮抗剂治疗慢性阻塞性肺疾病继发肺间质纤维化(PIF-COPD)的临床效果。方法选择收治的96例PIF-COPD患者为研究对象,随机将其分为对照组(n=48)与观察组(n=48)。对照组患者给予祛痰、支气管扩张剂、肺功能锻炼等常规治疗,观察组在常规治疗基础上行白三稀受体拮抗剂治疗。比较两组患者治疗效果。结果治疗后,两组MMRC评分均降低,FVC%、FEV1%及6MWT均显著升高,且观察组优于对照组(P<0.05)。结论白三烯受体拮抗剂治疗PIF-COPD效果显著,值得推广。
Objective To evaluate the clinical effect of leukotriene receptor antagonist in the treatment of chronic obstructive pulmonary disease-pulmonary interstitial fibrosis(PIF-COPD). Methods Ninety-six patients with PIF-COPD admitted in our hospital were selected as study objects. The patients were randomly divided into control group(n=48) and observation group(n =48). The control group was treated with routine treatment such as expectorant, bronchodilator and pulmonary function exercise. The observation group was treated with leukotriene receptor antagonist on the basis of routine treatment. The therapeutic effects of the two groups were compared. Results After treatment, the MMRC scores of the two groups decreased, FVC%, FEV1% and 6 MWT of the two groups significantly increased, and those in the observation group were better than the control group(P<0.05). Conclusion Leukotriene receptor antagonist is effective in the treatment of PIF-COPD, which is worthy of promotion.
Objective To evaluate the clinical effect of leukotriene receptor antagonist in the treatment of chronic obstructive pulmonary disease-pulmonary interstitial fibrosis(PIF-COPD). Methods Ninety-six patients with PIF-COPD admitted in our hospital were selected as study objects. The patients were randomly divided into control group(n=48) and observation group(n =48). The control group was treated with routine treatment such as expectorant, bronchodilator and pulmonary function exercise. The observation group was treated with leukotriene receptor antagonist on the basis of routine treatment. The therapeutic effects of the two groups were compared. Results After treatment, the MMRC scores of the two groups decreased, FVC%, FEV1% and 6 MWT of the two groups significantly increased, and those in the observation group were better than the control group(P<0.05). Conclusion Leukotriene receptor antagonist is effective in the treatment of PIF-COPD, which is worthy of promotion.
引文
[1]史碧君,张涛.慢性阻塞性肺疾病流行病学研究进展[J].预防医学,2015,25(4):366-369.
[2]赵辉,白亚娜,李密,等.老年人慢性阻塞性肺疾病住院状况及直接经济负担[J].中国老年学杂志,2016,36(5):1196-1198.
[3]贺琛,俞小卫.慢性阻塞性肺疾病合并肺间质纤维化37例临床分析[J].国际呼吸杂志,2016,36(5):350-352.
[4]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)(一)[J].中华结核和呼吸杂志,2013,36(4):255-264.
[5]杨建民,郑喜文,陈雪,等.CAT、mMRC评分在评估COPD患者分组中的差异性研究[J].中华全科医学,2017,15(7):1181-1184.
[6]杨宁,崔轶霞,张彩莲.老年慢性阻塞性肺疾病合并肺间质纤维化40例临床分析[J].陕西医学杂志,2015,44(10):1399-1401.
[7]刘晓明,张伟.论慢性阻塞性肺疾病合并肺纤维化的病因病机[J].中国中医基础医学杂志,2016,22(11):1463-1464.
[8]蔡明文,谭琳.布地奈德与泼尼松对慢性阻塞性肺疾病继发肺间质纤维化的肺功能及安全性对比[J].河北医学,2015,21(4):581-584.
[9]刘景平,栾照敏,韩瑜.白三烯受体拮抗剂治疗慢阻肺继发肺间质纤维化临床分析[J].国际医药卫生导报,2015,21(9):1267-1269.
[10]吕娇燕,邹琳琳,熊璎珞,等.LTB4-BLT1通路调控IL-13+及IL-17+细胞气道浸润参与博来霉素诱导的小鼠肺纤维化[C]//第九届全国免疫学学术大会,2014.
[11]余国雄.孟鲁司特钠对COPD继发肺间质纤维化患者肺功能以及运动耐力的影响[J].医学理论与实践,2017,30(20):3019-3020.
[2]赵辉,白亚娜,李密,等.老年人慢性阻塞性肺疾病住院状况及直接经济负担[J].中国老年学杂志,2016,36(5):1196-1198.
[3]贺琛,俞小卫.慢性阻塞性肺疾病合并肺间质纤维化37例临床分析[J].国际呼吸杂志,2016,36(5):350-352.
[4]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)(一)[J].中华结核和呼吸杂志,2013,36(4):255-264.
[5]杨建民,郑喜文,陈雪,等.CAT、mMRC评分在评估COPD患者分组中的差异性研究[J].中华全科医学,2017,15(7):1181-1184.
[6]杨宁,崔轶霞,张彩莲.老年慢性阻塞性肺疾病合并肺间质纤维化40例临床分析[J].陕西医学杂志,2015,44(10):1399-1401.
[7]刘晓明,张伟.论慢性阻塞性肺疾病合并肺纤维化的病因病机[J].中国中医基础医学杂志,2016,22(11):1463-1464.
[8]蔡明文,谭琳.布地奈德与泼尼松对慢性阻塞性肺疾病继发肺间质纤维化的肺功能及安全性对比[J].河北医学,2015,21(4):581-584.
[9]刘景平,栾照敏,韩瑜.白三烯受体拮抗剂治疗慢阻肺继发肺间质纤维化临床分析[J].国际医药卫生导报,2015,21(9):1267-1269.
[10]吕娇燕,邹琳琳,熊璎珞,等.LTB4-BLT1通路调控IL-13+及IL-17+细胞气道浸润参与博来霉素诱导的小鼠肺纤维化[C]//第九届全国免疫学学术大会,2014.
[11]余国雄.孟鲁司特钠对COPD继发肺间质纤维化患者肺功能以及运动耐力的影响[J].医学理论与实践,2017,30(20):3019-3020.